Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970121 | 0.85 | ADORA3 (0.56) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL29501901 | 0.85 | ADORA3 (0.60) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL20970138 | 0.83 | ADORA3 (0.43) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL20970112 | 0.83 | ADORA3 (0.43) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL19503480 | 0.83 | ADORA3 (0.48) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL20970142 | 0.82 | ADORA3 (0.47) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL20970111 | 0.82 | ADORA3 (0.47) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL20970193 | 0.80 | PARP1 (0.46) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL22018167 | 0.80 | ADORA3 (0.40) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL22018147 | 0.78 | ADORA3 (0.36) | ADORA3ADORA1ADORA2ATMEM97DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556903-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190127367-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556903-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | ADORA3 486/4885ADORA1 289/4885ADORA2A 379/4885 |
| US-20190127367-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | ADORA3 618/4885ADORA1 421/4885ADORA2A 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.